Overview

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Axitinib
Cisplatin
Pemetrexed